Skip to main content

15-06-2022 | EULAR 2022 | Conference coverage | Video

BE COMPLETE and BE OPTIMAL: How might bimekizumab impact PsA clinical practice?

Philippe Carron comments on the findings from the BE COMPLETE and BE OPTIMAL studies, and discusses how bimekizumab may impact the psoriatic arthritis treatment landscape if approved by the regulatory authorities (3:19).